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Abstract (315 wds) 
Objective 
Cerebral Autoregulation (CA) impairment may pose a risk factor for neurological complications 
among children supported by Extra-Corporeal Membrane Oxygenation (ECMO). Our first 
objective was to investigate the feasibility of CA continuous monitoring during ECMO treatment 
and to describe its evolution over time. The second objective was to analyze the association 
between CA impairment and neurological outcome. 
Design 
Observational prospective study. 
Patients and setting  
Twenty nine children treated with veno-arterial or veno-venous ECMO in the PICU of Nantes 
University Hospital, France and the PICU of the IRCCS Giannina Gaslini Institute in Genoa, 
Italy. 
Measurements 
A correlation coefficient between the variations of regional cerebral oxygen saturation (rSO2) 
and the variations of mean arterial blood pressure (MAP) was calculated as an index of CA 
(cerebral oxygenation reactivity index, COx). A COx > 0.3 was considered as indicative of 
dysautoregulation. COx – MAP plots were investigated allowing determining optimal MAP 
(MAPopt) and limits of autoregulation: lower (LLA) and upper (ULA). Neurological outcome was 




We included 29 children (median age 84 days, weight 4.8 kg). MAPopt, LLA and ULA were 
detected in 90.8 % (84.3-93.3) of monitoring time. Mean COx was significantly higher during day 
1 of ECMO compared to day 2 (0.1 (0.02-0.15)  vs 0.01 (-0.05-0.1), p=0.002). Twelve children 
experienced ANE (34.5%). The mean COx and the percentage of time spent with a COx > 0.3 
were significantly higher among ANE+ compared to ANE- patients (0.09 (0.01-0.23) vs 0.04 (-
0.02-0.06), p=0.04 and 33.3% (24.8-62.1) vs 20.8% (17.3-23.7) p=0.001). ANE+ patients spent 
significantly more time with MAP below LLA (17.2% (6.5-32.9) vs 5.6% (3.6-9.9), p=0.02) and 
above ULA (13% (5.3-38.4) vs 4.2% (2.7-7.4), p=0.004) respectively.  
 
Conclusions 
CA assessment is feasible in pediatric ECMO. The first 24 hours following ECMO represent  the 
most critical period regarding CA. Dysautoregulation is significantly more severe among patients 





Extra-corporeal membrane oxygenation (ECMO) is a life support therapy for critically ill children 2 
presenting severe respiratory or hemodynamic failure or during cardiac arrest. These patients 3 
present a high risk of developing ischemic or hemorrhagic neurologic complications  which lead 4 
to a significant morbidity and represent a substantial risk factor of mortality in this population 5 
(1,2). 6 
Cerebral autoregulation (CA) is a physiological protective mechanism aimed to maintain steady 7 
cerebral blood flow (CBF) over changes of mean cerebral perfusion pressure (CPP). In some 8 
cases mean arterial pressure (MAP) is considered instead of CPP, when intracranial pressure 9 
(ICP) is low and stable or cannot be monitored (3).  Even if CBF is not always  directly 10 
monitored at the bedside, several surrogates can be used and a wide variety of indices of 11 
correlation between the variations of these surrogates and CPP or MAP have been validated 12 
(4). In particular, in critically ill children, monitoring of the regional cerebral oxygen saturation 13 
(rSO2) is routinely available using near infrared spectrometry (NIRS). rSO2 is widely believed to 14 
reflect CBF slow fluctuations (0.005 to 0.05Hz), and the derived CA index is called Cerebral 15 
Oxygenation index (COx) (5). In adults and children, CA may be disturbed in varying conditions 16 
including traumatic brain injury (TBI), perinatal asphyxia, cardiac surgery, cardiac arrest or 17 
sepsis and impaired CA is usually associated with unfavorable outcome  (4,6–10). Furthemore, 18 
some studies in healthy newborn lambs have shown an impact of ECMO itself on CA (11,12). 19 
In this overall context, CA impairment in critically ill patients treated by ECMO may be a key 20 
factor in the genesis of neurological complications. Recent preliminary studies using different 21 
methods have suggested an association with CA disorders and neurological outcome among 22 
children supported by ECMO (13–15).  23 
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In this context, the aim of our pilot study was to investigate the feasibility of continuous 24 
monitoring of CA in children supported by ECMO and to desciribe its evolution overtime and its 25 




Study design 30 
This prospective observational study was conducted from July 2018 to September 2019 in the 31 
respectively 12-bed and 20-bed surgical and medical Pediatric Intensive Care Units (PICU) of 32 
the University-affiliated hospital in Nantes, France and the IRCCS Giannina Gaslini Institute in 33 
Genoa, Italy.  34 
 35 
Patients 36 
Patients from 0 to 15 years treated by veno-arterial (VA) or veno-venous (VV) ECMO for 37 
hemodynamic or respiratory failure or during cardiac arrest resuscitation were included. The 38 
study was approved by the local Ethics Committees. Information of the parents was provided 39 
before inclusion. The only exclusion criterion for was a parental refusal. Clinical informations on 40 
medical history, clinical and biological parameters at PICU admission and during the PICU stay 41 
were collected prospectively.  42 
 43 
Patient management under ECMO  44 
Patients were treated according to the local practice of each center. After surgical or 45 
percutaneous cannulation, all the patients were placed on centrifugal pumps (Deltastream, 46 
Medos®, Germany, for Nantes and Centrimag, Thoratec Corporation®, Pleasanton, USA, for 47 
Genoa). For VA ECMO, cannulation was central through the ascending aorta and the right 48 
atrium, or peripheral through right carotid artery and right internal jugular vein or through 49 
femoral vessels depending on the indication and the age of the patient. For VV ECMO, 50 
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cannulation was through right internal jugular vein using double lumen cannulae (Avalon Elite®, 51 
Maquet, Germany) or through femoral vein and right internal jugular vein. Membrane 52 
oxygenator and circuitry were changed when fibrin deposition or thrombi had deleterious effects 53 
on blood oxygenation, platelet count or blood fibrinogen level decreased significantly or 54 
significant intravascular hemolysis appeared. In the two centers, heparin was the 55 
anticoagulation drug of choice. After a loading dose (50 to 100 UI/kg) at the time of cannulation, 56 
all patients were continuously infused with unfractionated heparin and the dose was adapted at 57 
least once a day according to the anti-Xa activity (targeting 0.3 to 0.5). Antithrombin III and 58 
platelet count measured at least once a day were maintained above 70% and 50 000/mm3 59 
respectively. 60 
All children were sedated with a combination of midazolam and morphine, fentanyl or 61 
sufentanyl. Ketamine and dexmedetomidine were added if clinically indicated. 62 
Arterial blood gas analysis was performed during the first hour following ECMO start and 63 
thereafter at least twice a day. Oxygenation was primarily managed adjusting FiO2 on the 64 
ECMO blender, targeting SpO2 from 88 to 97%. Gas flow in the blender was settled according 65 
to the blood gas measurement, targeting pH 7.30 to 7.45 and PaCO2 35 to 45 mmHg. 66 
 67 
Autoregulation monitoring 68 
Routine hemodynamic and cerebral monitoring devices were used for the study. The only 69 
project-specific addition to the standard monitoring setup was calculation of CA, blinded for all 70 
the clinicians including radiologists. Arterial blood pressure (ABP) was continuously monitored 71 
from an indwelling radial or femoral arterial catheter (MX700 for Nantes, MX800 for Genoa, 72 
Phillips®, Netherlands). NIRS pediatric sensors were placed at least on the left forehead 73 
(bilaterally in some patients) and rSO2 was continuously measured (INVOS 5100C, Medtronic®, 74 
Ireland). All signals were collected digitally, resampled at a frequency of 100 Hz and integrated 75 
using a laptop computer with ICM+ software (https://icmplus.neurosurg.cam.ac.uk, University of 76 
Cambridge, Cambridge Enterprise Ltd, Cambridge, UK). The same software was used to 77 
process ABP and rSO2 waveforms retrospectively as follows. Only the monitoring of left rSO2 78 
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and periods corresponding to the ECMO run were selected.  For patients who experienced 79 
brain death, only monitoring prior to the clinical diagnosis of brain death was considered. 80 
Artefacts of ABP and rSO2 were manually identified and excluded for further analysis. MAP was 81 
calculated as the 10sec time averaged value of ABP.  CA was assessed with the COx index, 82 
which uses variations in the rSO2 signal as a surrogate of changes in CBF. COx was calculated 83 
as a moving correlation coefficient between MAP and the mean rSO2 (thus filtering out high-84 
frequency waves from pulse and respiration) from 300-s duration data segments, thereby 85 
utilizing 30 data points for each COx calculation, and was updated every minute. In case of CA 86 
impairment, COx approaches 1, indicating that the CBF is blood pressure passive, while when 87 
MAP is within the limits of CBF autoregulation, COx decreases. However, the absolute COx 88 
cutoff for CA impairment is not entirely established, especially in this particular condition, but is 89 
likely between 0.3 and 0.5 (5,16). We have followed (9) and chose the value of 0.3 as the 90 
autoregulatory threshold. With that, several different summary (per-patient) metrics of CA could 91 
be calculated including the mean value, the percentage time spent with a COx above 0.3, the 92 
area under the curve (AUC) of COx>0.3 during time. As CA monitoring duration differed from 93 
patient to patient, we normalized AUC by dividing it by the duration of the recording expressed 94 
in hours. Cox values were averaged for each day after ECMO start. 95 
 96 
Assessment of optimal MAP, lower and upper limits of autoregulation 97 
Optimal MAP (MAPopt), lower and upper limits of autoregulation (LLA and ULA respectively) 98 
were calculated using a multiwindow approach inspired by Depreitere et al., subsequently 99 
implemented in ICM+, investigated in a retrospective traumatic brain injury data set (17,18), and 100 
recently adjusted for prospective bedside use by Beqiri et al. (19). In this study, we adapted the 101 
algorithm to our clinical population and to the signals available, therefore only an overview of 102 
the approach is given below, highlighting the main differences with the algorithm as described 103 
by Beqiri et al.  At each time point, 36 COx-MAP plots were generated from past data windows 104 
of increasing duration ranging from 2 to 8 hours, using incremental steps of 10 min. The data 105 
points were divided into groups corresponding to MAP bins of 2 mmHg length within 20–120 106 
9 
 
mmHg range of MAP values and where each MAP bin must represent at least 2% of the total 107 
data count. For each bin, mean (Fisher transformed) COx and MAP values were used to fit a 108 
second order polynomial describing the theoretical U-shape, with its nadir determining MAPopt, 109 
and with LLA and ULA defined by the MAP values at COx = 0.3 (figure 1). This process was 110 
repeated for each progressively longer data window. Individual results were filtered using a set 111 
of quality control criteria and the accepted values were combined using weighted average 112 
operation. The calculations were repeated every minute and the resulting time series were 113 
finally subjected to an exponentially weighted average filter of 2 hours of duration forming the 114 
MAPopt, LLA and ULA time trends. The missing data limit of the calculation was set at 75%, 115 
therefore at least 2 hours of data were necessary to generate the first MAPopt value. As shown 116 
in supplemental digital content-figure 1, this method allowed building continuous curves of 117 
MAPopt, ULA and LLA. The feasibility of the methodology was assessed using a metric of the 118 
percentage of MAP monitored time when MAPopt, LLA and ULA were available. The difference 119 
between median MAP and MAPopt was calculated continuously (ΔMAPopt = median MAP-120 
MAPopt). The percentage of time spent with a MAP more than 5 mmHg below (ΔMAPopt<-121 
5mmHg), more than 5 mmHg above (ΔMAPopt>5 mmHg), or close to (ΔMAPopt = -5 to 5 122 
mmHg) MAPopt was calculated for each patient. Percentage of time below LLA and above ULA 123 
and AUC of MAP below LLA and above ULA were also calculated and these values were 124 
averaged for each day after ECMO start. 125 
 126 
Neurological outcome 127 
No specific clinical or neuroimaging assessment protocol was introduced during the study. For 128 
neonates and children with open fontanels, head ultra-sound (HUS) was performed during the 129 
pre-ECMO period if possible, every day during the ECMO run and at least once after ECMO 130 
discharge. When available, patients in the two PICUs were monitored by continuous amplitude 131 
integrated electroencephalography (aEEG) and/or discontinuous electroencephalography 132 
(EEG). For all patients, in case of any ongoing concern of their neurological status, an emergent 133 
computed tomography (CT) while on ECMO and/or post ECMO magnetic resonance imaging 134 
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(MRI) could be performed. Patient outcome was assessed by the onset of any Acute Neurologic 135 
Event (ANE) during ECMO support. Patients presenting hemorrhagic or ischemic stroke and/or 136 
clinical or electrical seizure and/or brain death were considered ANE+ (20,21). The timing of 137 
ANE onset was defined as the delay between ECMO start and  the first clinical and/or electrical 138 
manifestation corresponding to ANE.  139 
 140 
Statistical analysis 141 
Baseline characteristics were reported as median (interquartile range) or mean (standard error 142 
of the mean) and n (%) for quantitative and qualitative variables, respectively.  Inter-group 143 
comparisons were performed by using the Mann–Whitney U test for continuous variables and 144 
Chi-square test or Fisher’s test when appropriate for categorical variables.The Wilkoxon signed-145 
rank test was used to compare values between  days of ECMO. p value of less than 0.05 was 146 





Baseline characteristics and outcome  152 
All the 29 screened patients were included during the study period as no patient met the 153 
exclusion criterion. These 29 patients underwent 31 ECMO runs (including 22 VA runs and 9 154 
VV runs) as 2 patients were converted from VA to VV ECMO. At least one neuroimaging 155 
procedure was performed in 25/29 (86%) patients (HUS n=17, CT n=7, MRI n=13) and 24/29 156 
(82.8%) children were monitored by continuous aEEG, completed by discontinuous 157 
conventional EEG if necessary. Twelve of the 29 patients (41.4%) were considered ANE+. 158 
Baseline characteristics of the whole  population and  according to the ANE+/ANE- status are 159 
described in table 1 and the case analysis summary of ANE+ patients is presented in table 2. 160 
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The 4 patients without neuroimaging presented no clinical or electrical neurological complication 161 
and were considered ANE- as the 5 patients without any EEG monitoring.  162 
 163 
Autoregulation monitoring 164 
Among the whole cohort, the median cerebral autoregulation monitoring time was 79.4 hours 165 
(44.8-115.2) corresponding to 65 % (43.4-89.8) of ECMO run duration. Absolute monitoring time 166 
and monitoring time related to the ECMO length were not different comparing ANE- and ANE+ 167 
patients (82hours (49.4-205) vs 66.1hours (43.6-111.6),p =0.53 and 51.9% (81.2-206) vs 73.3% 168 
(61-96.6), p=0.18). COx measurement was available in all the 29 monitored patients and 169 
MAPopt, LLA and ULA were available 90.8% (84.3-93.3) of monitoring time. As shown in 170 
supplemental Digital Content- table 1. CA metrics were not different comparing VA an VV 171 
ECMO runs.The evolution of Cox and of the percentage of time spent with a MAP below LLA 172 
and above ULA over ECMO run  in the whole cohort are shown in figure 2. The results of CA 173 
metrics in the whole cohort and according to the ANE-/ANE+ status are presented in figure 3 174 
and their evolution over time according to the neurological outcome in figure 4.  175 
 176 
Discussion 177 
We report an  exploratory study focusing on CA monitoring in ECMO children. The first 178 
important result is that continuous CA monitoring at the bedside using routine monitoring 179 
devices is feasible. COx was available in all monitored patients and MAPopt, LLA and ULA 180 
were obtained in 90.8% of the monitored time using a Multi-Window approach. We report that 181 
the first 24 hours of ECMO represent the most critical period regarding CA. Children who 182 
developed ANE had higher COx and spent significantly more time above the autoregulatory 183 
threshold of COx>0.3 during ECMO run.  MAP was below LLA and above ULA over longer time 184 
in ANE+ compared to ANE- patients, especially within the initial period after ECMO start.  185 
In our cohort, the incidence of ANE was 34.5%. As a comparison, Hervey- Jumper et al 186 
reported an incidence of overall stroke of 13.1% among 31 335 ECMO patients in the US (22). 187 
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This difference is largely due to the sensitivity of our outcome measure that includes clinical, 188 
electrophysiological and radiological neurological evaluations. In a recent study, among 70 189 
children treated by ECMO and continuously monitored by EEG, 23% presented 190 
electroencephalographic seizures, close to what we have seen in our patients (23). ANE has 191 
been previously used to compare critically ill adults and children of various ages and appears 192 
relevant for evaluating early overall neurological impairment (20,21,24). This incidence may also 193 
be explained by the young age at cannulation (median age 84 days, 27.6% of neonates) and a 194 
high rate of patient cannulated after cardiac surgery (31%) which are well known risk factors for 195 
neurological complication under ECMO (22).  196 
Another controversial point is the choice of 0.3 as the COx cut-off as various cut-offs of COx 197 
and other CA indexes are used in the literature (4). However, all the statistical analyses 198 
presented in this report were also performed with the cut-offs of 0.2 and 0.4 with comparable 199 
results (data not shown). 200 
CA metrics were not different during VA or VV runs, with the limitation that only 9 VV ECMO 201 
runs were studied. This could be surprising as patients cannulated in VA ECMO are 202 
hemodynamically unstable and one can imagine that direct arterial perfusion by a non-pulsatile 203 
flow may have severe impact on CA. However, patients in VV ECMO also present risk factors of 204 
cerebral hemodynamic disruption like PCO2 and PO2 variations or sepsis and animal models 205 
have also shown impairment of CA during VV ECMO (25).  206 
In agreement with previous studies (23,26) our data suggest that mostly ANE occur within the 207 
first 24 hours after ECMO start. Our study adds that this period also represents the most critical 208 
time with regards with CA disorders. Interstingly, recent studies have reported the independant 209 
relationship between a large decrease of PCO2 immediately after ECMO start and the risk of 210 
cerebral damage (27,28). In this context, all the data are consistent to conclude that this period 211 
requires particular attention in clinical practice and in further studies.  212 
The triggers of CA deterioration are very challenging to investigate individually at the bedside. In 213 
particular, the specific impact of ECMO itself suggested by animal studies (11,12) is impossible 214 
to analyze with such studies. Indeed, before ECMO start, all these patients experienced severe 215 
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medical condition (cardiac arrest, associated TBI, septic shock, cardio pulmonary bypass, 216 
perinatal anoxo ischemia, etc ) which are all well known risk factors of CA impairment (4,6–10). 217 
Furthermore, as most ANE occur promptly after ECMO start, during the most critical period with 218 
regards of CA, their causal relationship remains unclear. Indeed, the timing of ANE is too 219 
imprecise to compare CA before and after its onset.   220 
In such critically ill patients, neurological outcome is multifactorial and the primary cerebral insult 221 
caused by the underlying disease may have a very strong impact. However, the limitation of 222 
secondary injuries appears crucial and the control of CA regardless of its trigger represents an 223 
interesting candidate. In this context, like in other conditions, the MAP level, may be a key 224 
target. The association between low blood pressures and poor neurological outcome that we 225 
have shown, appears intuitive. Interstingly, our data also suggest a strong association between 226 
the time above ULA and the risk of ANE which is an unusual result comparing with CA studies 227 
in other conditions. As some studies have shown critical increase of MAP after ECMO onset, 228 
this appears as an underestimated potential secondary controllable factor (29,30). In our study, 229 
the mean MAP within the first 24 hours was significantly higher among ANE+ patients. This 230 
result is interesting but needs to be considered with much caution as, even this was not 231 
statistically significant, the patients of the ANE+ group were slightly older. The impact of other 232 
candidates like PO2 and PCO2 variations, ECMO settings or sedative agents on CA need to be 233 
investigated. Subsequently, the following steps will be to investigate the ability of clinicians to 234 
improve CA at the bedside and, next, to improve outcome using CA-oriented therapy.  235 
Limitations 236 
First, the main limitation of this exploratory study is the small size of the cohort including  237 
different patients, ECMO modes and types of cannulation. Our preliminary results will need to 238 
be confirmed in larger cohorts and further study will need to focus on specific medical conditions 239 
and age groups. Secondly, CA monitoring was performed only within about two third of ECMO 240 
time, due to connection delay. Even this appears representative and clinically useful, this may 241 
be easily optimized by a better training of the teams to CA monitoring initiation. Furthermore, 242 
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this study reports only results issued from left rSO2, justified as all patients were monitored by 243 
almost left NIRS but only 19/29 had bilateral monitoring. However, Papademetriou et al have 244 
shown some differences regarding oxygenation between the two cerebral hemispheres among 245 
infants treated by ECMO (31).  Third, we report a univariate analysis of the association between 246 
CA metrics  and neurological outcome as the small size of the cohort is a limitation for adjusting 247 
for suspected confounding factors. Finally, here we explore only the effect of MAP on CA, 248 
neglecting CPP. However, ICP may be raised is some of these patients (for example after 249 
cardiac arrest) and the investigation of ICP by non-invasive methods may be a key point to 250 
understand better CA disorders (32,33).   251 
 252 
Conclusion  253 
 254 
Our study confirms the feasibility of monitoring cerebral autoregulation in paediatric patients 255 
supported by ECMO using routine clinical practice monitoring devices. The first 24 hours seem 256 
to be the most critical period with regards to dysautoregulation and an association was found 257 
between the CA deterioration and the incidence of ANE. Further studies are needed to 258 
understand better the underlying mechanisms of CA impairment under ECMO in order to 259 
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Figure 1. Screenshot of a 8 hour epoch of autoregulation monitoring in a one year old patient 
under ECMO. Chart A, evolution of MAP expressed in mmHg over time. Chart B, evolution of 
left COx over time. Chart C, risk chart whereby a negative COx is denoted by a green color, 
a COX between 0 and 0.3 by orange color and a Cox >0.3 (considered as critical) by red 
color. Chart D, percentage of time passed in each division of 0.1 of COx. The right part of the 
chart colored in red corresponds to the percentage of time passed in “critical zone” 
(COx>0.3). Chart E, COx values averaged (represented as mean and standard error) into 
bins of MAP spanning 2 mmHg. The horizontal white line represents the COx value of 0.3. U 
shape curve is fitted. As mentioned in the chart, the nadir of this curve (around 55 mmHg) 
represents the MAPopt for this period and the intersection between the U shape curve and 
the horizontal white line gives the LLA (around 49 mmHg) and the ULA (about 59 mmHg). 
MAP, Mean Arterial Pressure; COx, Cerebral Oxygenation index; MAPopt, optimal MAP; 






Figure 2. Evolution of cerebral autoreguilation metrics overtime after ECMO start in 
the whole cohort. Values represent mean values +/- SEM. The Wilcoxon signed-rank 
test was used to compare the values two by two. * p<0.05, considered as significant 
A. Evolution of Cox B. Evolution of the percentage of time spent with MAP below LLA 
and above ULA respectively.  
COx, Cerebral Oxygenation index; MAP, Mean Arterial Pressure; LLA, lower limit of 
autoregulation;  ULA, upper limit of autoregulation. 
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Figure 3. Autoregulation metrics in the whole cohort and according to neurological outcome 
during the whole ECMO run. A. mean MAP, mean MAPopt, mean LLA and mean ULA B. 
Mean Cox C. Percentage of time with Cox> 0.3 D. Percentage of time with MAP – MAPopt 
between  -5 and +5 mmHg E. Percentage of time with MAP < LLA.  F. Percentage of time 
with MAP >ULA.  
Data are shown in box-and-whisker plots, indicating the median, interquartile range, and 
range. The Mann–Whitney test was used to compare the 2 groups of infants.  
COx, Cerebral Oxygenation index; MAP, Mean Arterial Pressure; ΔMAPopt = median 
MAP-MAPopt; LLA, lower limit of autoregulation;  ULA, upper limit of autoregulation. 
 
 





















































































































Figure 4. Evolution of cerebral autoreguilation metrics overtime after ECMO start according 
to neurological outcome. Values represent mean values +/- SEM for each group. The Mann–
Whitney test was used to compare the 2 groups. * p<0.05, considered as significant. A. 
Evolution of MAP B. Evolution of LLA C. Evolution of ULA D. evolution of Cox E. Evolution of 
the percentage of time spent with MAP below LLA. F. Evolution of the percentage of time 
spent with MAP above ULA. 
COx, Cerebral Oxygenation index; MAP, Mean Arterial Pressure; LLA, lower limit of 
autoregulation;  ULA, upper limit of autoregulation. 











































































































Supplemental Digital Content-Figure 1. Screenshot of a 8 hour epoch of autoregulation 
monitoring in a patient under ECMO. Red line represents measured MAP, blue line 
represents MAPopt and the blue zone corresponds to the area between ULA and LLA. 
Periods with MAP>ULA (A) and with MAP < LLA (B) are noticed in the figure. 
MAP, Mean Arterial Pressure; MAPopt, optimal MAP; LLA, lower limit of autoregulation; ULA, 






Table 1. Characteristics of the patients in the whole cohort and according to 
ANE+/ANE- status  
 
Characteristic Whole cohort ANE - (n=17) ANE + (n=12) p value 
Age (months) 2.8 (0.4-42.5) 2.3 (0.06-6.7) 31.2 (1.8-68.8) 0.18 
Weight (kg) 4.8 (3.2-15) 4.1 (3.2-6.1) 13.5 (4.8-19) 0.09 
Neonates (<28 days)  8 (27.6) 6 (35.3) 2 (16.7) 0.25 
Male  18 (62.1) 10 (58.8) 8 (66.6) 0.48 
Chromosomic anomaly 5 (17.2) 4 (23.5) 1 (8.3) 0.29 
Indication    0.36 
 Haemodynamic 18 (62.1) 10 (58.8) 8 (66.6)  
 Respiratory 10 (34.5) 7 (41.2) 3 (25)  
 ECPR 1 (3.4) 0 (0) 1 (8.3)  
Cannulation by mobile unit  5 (17.2) 2 (11.8) 3 (25) 0.33 
Post cardiotomy ECMO     
 Number of patients 9 (31) 7 (41.2) 2 (16.7) 0.22 
 Time of CPB (min) 210 (90.5-285) 239 (130-300) 81 (66-) 0.1 
Oxygenation parameters for 
respiratory ECMO 
    
 Oxygenation index 30.7 (9-39) 26.2 (5.2-36.1) 38.9 (32.5-43.4) 0.13 
 PaO2/FiO2  57 (49-325.8) 57 (51-211.8) 48.8 (33.8-) 0.31 
Cardiac arrest before or during 
cannulation 
    
 Number of patients 7 (24.1) 2 (11.8) 5 (41.6) 0.08 
    Total time until ROSC 
(min) 
11.5 (3.2-33.7) 21 (7-28) 10 (2.7-31.2) 0.65 
pH before cannulation 7.15 (7.05-7.34) 7.27 (7.15-7.43) 7.05 (6.95-7.18) 0.001 
Lactate before cannulation 
(mmol/l) 
5.2 (2.2-9.5) 3.2 (1.4-5.4) 9.5 (5.6-14) 0.004 
ECMO VAa   22 (75.9) 12 (70.6) 10 (83.3) 0.37 
First cannulation sitea    0.09 
 VA (n= 22)     
  Central 10 (34.5) 8 (47.1) 2 (16.7)  
  Leg 2 (6.9) 1 (5.9) 1 (8.3)  
  Neck 10 3 (17.6) 7 (58.3)  
 VV (n=7)     
      Internal jugular veinb  6 (20.7) 4 (23.5) 2 (16.7)  
      Femoral/ jugular veins 1 (3.4) 1 (5.9) 0 (0)  
ECMO duration (hours)  81 (48.5-160) 94 (49.5-460) 61.5 (45-94) 0.16 
Outcome     
 Lenght of mechanical 
ventilation (days) 
10.5 (5.5-17.7) 12.5 (5.5-19.5) 9.5 (7.5-14.7) 0.25  
 PICU LOS 17 (9.5-30) 21 (9.5-50.5) 12.5 (8.5-18.7) 0.12 
 Hospital LOS (days) 37 (14-68) 45 (18.5-75) 23 (8.7-51.7) 0.17 
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 Alive H24 ECMO 
discharge 
19 (65.5) 12(70.5) 7 (58.3) 0.38 
 Alive at hospital 
discharge 
14 (48.3) 8 (47.1) 6 (50) 0.58 
 
Data are expressed as median (interquartile ranges) or n (% of the number of patients of the column). 
p<0.05 was considered significant.  No correction for multiple comparison was applied. 
ECPR, Extra-corporeal CardioPulmonary Resuscitation; CPB, CardioPulmonary Bypass; ROSC, 
Return Of Spontaneous Circulation;PICU, Pediatric Intensive Care Unit; LOS, Length Of  Stay; VA, 
veno arterial; VV, veno venous 
a Here is reported the first site of cannulation. Cannulation was further converted to VV (Jugular 
vein/Femoral vein) in 2 patients.   




Table 2. Case analysis summary for patients who met the criteria of ANE. 
 
























1 4 y Myocarditis Yes VA Neck Right 
watershed 
cerebral 







No D1 Alive 
2 9 y Sicle cell 
disease, 
ARDS 





No No NA Alive 
3 0 d Meconium 
aspiration,HIE 









Electrical No D4 Alive 
4 6 d CDH No VA Neck No Electrical No D1 Alive 






No No NA Alive 




No No D1 Dead 
7 2 mo AVSD,  Post 
operative 




8 2 mo TOF ,post 
operative 
septic shock 
Yes VA Chest No Clinical 
and 
electrical 
No D1 Dead 
9 6 y Drowning Yes VV Neck NA Clinical 
and 
electrical 
No D1 Dead 




No No D1 Alive 
11 2 mo Pertussis No VA Neck NA No Yes D3 Dead 
12 2 y Cardiogenic 
shock 
Yes  Neck No Electrical Yes D1 Dead 
 
aTiming of ANE after ECMO start corresponds to the date of the first clinical and/or electrical 
manifestations of ANE after ECMO start. VA, venoarterial; VV, venovenous; ARDS, Acute 
Respiratory Distress Syndrome; HIE, Hypoxic_Ischemic Encephalopathy; CDH,  Congenital 
Diaphragmatic Hernia ; AVSD, Atrio Ventricular Septal Defect; LCOS, Low Cardiac Output 
Syndrom; TOF,Tetralogy of Fallot 
 
Supplemental Digital Content-table 1. Autoregulation parameters during ECMO run 
according to the type of cannulation. 
 
Variable VA runs (n=22) VV runs (n=9) p value 
Age (months) 2.26 (0.3-25.6) 8.1 (0.5-99.7) 0.39 
Time of monitoring (hours) 67.7 (23.6-93) 113.8 (85.7-354.6) 0.009 
Time of monitoring / ECMO duration (%) 67.6 (41.5-90.7) 64.3 (41.3-97.2) 1 
Mean COx 0.04 (-0.01-0.12) 0.03 (-0.04-0.06) 0.65 
% time with COx> 0.3 24.2 (21.5-34.2) 20.4 (14.4-30.9) 0.149 
COx (AU) > 0.3 /hour x 100 4.6 (3.5-6.3) 3.84 (2.3-5.1) 0.32 
% time MAPopt, LLA and ULA available 90.9 (81.2-93.4) 90.7 (81.1  -93.3) 0.31 
Mean MAP (mmHg) 52.6 (48.8-60.5) 61.3 (44.8-78.1) 0.32 
Mean MAPopt 54.1 (47.9-62.5) 63.3 (46-71.7) 0.28 
Mean LLA 45.3 (37.6-55.1) 51.9 (37.6-64.2) 0.32 
Mean ULA 63 (56.7-69.8) 72.1 (55.3-87.9) 0.21 
% time ΔMAPopt -5 to +5 mmHg 62.5 (50.7-66.2) 59 (49.2-63.8) 0.62 
% time ΔMAPopt < - 5 mmHg 22.3 (9.4-26.4) 23.6 (13.6-30.2) 0.59 
% time ΔMAPopt > 5 mmHg 15.2 (9.6-22.7) 17.4 (8.5-25.8) 0.65 
% time MAP < LLA 7.9 (4.9-24) 6.95 (3.3-9.2) 0.44 
% time MAP > ULA 5.7 (3.1-13.6) 7.16 (3.4 -14.4) 0.76 
26 
 
% time MAP < LLA or MAP > ULA 12.6 (9.9-40.5) 12.5 (9.3-21.2) 0.68 
Data are expressed as median (interquartile ranges). p<0.05 was considered significant.  No 
correction for multiple comparison was applied. 
COx, Cerebral Oxygenation index; AU, Area Under; MAP,Mean Arterial Pressure; LLA,Lower Limit of 
Autoregulation; ULA, Upper Limit of Autoregulation; ΔMAPopt = median MAP-MAPopt 
 
